MARKET

APGE

APGE

Apogee Therapeutics Inc
NASDAQ
74.78
-2.03
-2.64%
After Hours: 75.56 +0.78 +1.04% 19:29 12/16 EST
OPEN
75.40
PREV CLOSE
76.81
HIGH
77.50
LOW
74.52
VOLUME
1.10M
TURNOVER
--
52 WEEK HIGH
78.15
52 WEEK LOW
26.20
MARKET CAP
5.11B
P/E (TTM)
-17.1415
1D
5D
1M
3M
1Y
5Y
1D
Apogee Therapeutics initiated with an Overweight at Stephens
TipRanks · 5h ago
Weekly Report: what happened at APGE last week (1208-1212)?
Weekly Report · 1d ago
Apogee Therapeutics CEO Michael Henderson Reports Sale of Common Shares
Reuters · 4d ago
Apogee Therapeutics (APGE) Receives a New Rating from Roth MKM
TipRanks · 6d ago
3 ‘Strong Buy’ Stocks to Buy Today, 12/10/2025, According to Top Analysts
TipRanks · 6d ago
This Amazon Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Benzinga · 6d ago
Apogee Therapeutics Initiated at Buy by Deutsche Bank
Dow Jones · 6d ago
Apogee Therapeutics Price Target Announced at $103.00/Share by Deutsche Bank
Dow Jones · 6d ago
More
About APGE
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Rα. APG279 is for the dual inhibition of OX40L and IL-13.

Webull offers Apogee Therapeutics Inc stock information, including NASDAQ: APGE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APGE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APGE stock methods without spending real money on the virtual paper trading platform.